This listing of the claims will replace all prior versions, and listings, of claims in the application.

LISTING OF THE CLAIMS

1. (Previously presented) A pharmaceutical composition comprising at least one A_{2a} receptor agonist selected from the group consisting of CVT-3146, named (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide, which has the formula:



CVT-3033, named (4S,2R,3R,5R)-2-[6-amino-2-(1-pentylpyrazol-4-yl)purin-9yl]-5-(hydroxymethyl)oxolane-3,4-diol, which has the formula:



and combinations thereof, at least one liquid carrier, wherein said at least one liquid carrier comprises water, distilled water, de-ionized water, saline, a buffer, or combinations thereof, and at least one co-solvent, wherein said at least one co-solvent comprises methylboronic acid or borate buffer, and wherein the pH of said pharmaceutical composition is from about 8.5 to about 10.

2-4. (Canceled)

5. (Previously presented) The pharmaceutical composition of claim 1 wherein the co-solvent is methylboronic acid.

6. (Original) The pharmaceutical composition of claim 5 wherein the A_{2a} receptor agonist is CVT-3146.

7. (Original) The pharmaceutical composition of claim 6 wherein the CVT-3146 is present in an amount ranging from about 50 micrograms/ml to about 250 micrograms/ml and the methylboronic acid is present in an amount from about 0.4% to about 0.6% (w:v).

8. (Previously presented) The pharmaceutical composition of claim 7 wherein the liquid carrier ~~is~~ comprises at least one buffer.

9. (Canceled)

10. (Previously presented) The pharmaceutical composition of claim 1 wherein the pH is from about 9.1 to about 9.4.

11. (Previously presented) The pharmaceutical composition of claim 1 wherein the co-solvent is a borate buffer.

12. (Original) The pharmaceutical composition of claim 6 wherein the co-solvent is about 0.5% (w:v) methylboronic acid.

13. (Original) The pharmaceutical composition of claim 12 wherein said composition also comprises a buffer to bring the pH of the composition to about 9.3.

14. (Original) The pharmaceutical composition of claim13 wherein the CVT-3146 in said composition is present in an amount from about 50 to about 150 micrograms/ml.

15. (Original) The pharmaceutical composition of claim 14 wherein the said composition also comprises about 0.55% (w:v) sodium chloride and about 50 mM sodium bicarbonate.

16. (Previously presented) The pharmaceutical composition of claim 63 wherein the co-solvent is propylene glycol and said propylene glycol is present in an amount from about 5% to about 25% (w:v).

17. (Original) The pharmaceutical composition of claim 16 wherein the propylene glycol is present in an amount from about 8% to about 20% (w:v).

18. (Canceled)

19. (Previously presented) The pharmaceutical composition of claim 17 wherein the said composition further comprises EDTA.

20. (Original) The pharmaceutical composition of claim 16 wherein the A_{2a} receptor agonist is CVT-3146 and said CVT-3146 is present in an amount from about 50 to about 150 micrograms.

21. (Previously presented) A method of producing coronary vasodilation without significant peripheral vasodilation comprising administering to a human the pharmaceutical composition of claims 1 or 5 or 62 wherein said composition contains about 10 to about 600 micrograms of at least one A_{2a} receptor agonist.

22. (Original) The method of claim 21 wherein the A_{2a} receptor agonist is CVT-3146.

23. (Previously presented) The method of claim 22 wherein said pharmaceutical composition is administered by intravenous (iv) bolus.

24. (Original) The method of claim 23 wherein said pharmaceutical composition is administered in about 10 to about 20 seconds.

25. (Previously presented) A method of myocardial perfusion imaging of a human comprising administering a radionuclide and the composition of claims 1 or 5 or 62 either simultaneously or sequentially to a human wherein the myocardium is examined for areas of insufficient blood flow following administration of the radionuclide and the composition.

26. (Original) The method of claim 25 wherein the myocardium examination begins within about 1 minute after the radionuclide and the composition are administered.

27. (Original) The method of claim 26 wherein the A_{2a} receptor agonist in said composition causes at least a 2.5 fold increase in coronary blood flow, such increase in blood flow being achieved for less than about 5 minutes.

28. (Previously presented) The method of claim 25 wherein the A_{2a} receptor agonist in said composition is CVT-3146, which CVT-3146 is administered in an amount of from about 10 to about 600 micrograms in a single ~~iv~~ intravenous (iv) bolus.

29. (Original) The method of claim 28 wherein the CVT-3146 amount is from about 100 to about 500 micrograms.

30. (Original) The method of claim 28 wherein the CVT-3146 amount is about 400 micrograms.

31. (Original) The method of claim 28 wherein said composition is administered in about 10 to about 30 seconds or less.

32-61. (Canceled)

62. (Previously presented) A pharmaceutical composition comprising at least one A_{2a} receptor agonist selected from the group consisting of CVT-3146, named (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide, which has the formula:



CVT-3033, named (4S,2R,3R,5R)-2-[6-amino-2-(1-pentylpyrazol-4-yl)purin-9yl]-5-(hydroxymethyl)oxolane-3,4-diol, which has the formula:



and combinations thereof, at least one liquid carrier, wherein said at least one liquid carrier comprises water, distilled water, de-ionized water, saline, a buffer, or combinations thereof, and at least one co-solvent, wherein said at least one co-solvent comprises propylene glycol or polyethylene glycol, and wherein said pharmaceutical composition has a pH of from about 6 to about 8.

63. (Previously presented) The pharmaceutical composition of claim 62 wherein said co-solvent is propylene glycol.